1. Geerts WH, Bergqvist D, Pineo GF, Heit JA,
Samama CM, Lassen MR. Prevention of
venous thromboembolism. Chest.
2008;133:381S-453S
2. Warwick D, Friedman RJ, Agnelli G, Gil-Garay
E, Johnson K, FitzGerald G, et al. Insufficient
duration of venous thromboembolism
prophylaxis after total hip or knee replacement
when compared with the time course of
thromboembolic events. J Bone Joint Surg [Br].
2007;89-B:799-807.
1. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of Action Pharmacokinetics, Dosin
Considerations, Monitoring, Efficacy and Satefy. Chest. 1992;102;337S-351S
2. Mueller RL, Scheidt S. History of Drugs for Thrombotic Disease. Circulation. 1994;89:432-449
3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lasen MR, Colwell CW et al. Prevention of Venous
Thromboembolism. Chest. 2004;126(3 Suppl):338S-400S.
4. Turpie AG. Arterioscler Thromb Vasc Biol. 2007;27:1238-1247
5. Hirsh J, Levine MN, Low molecular weight heparin. Blood 1992;79:1-17
6. Nutescu EA. Antithrombotic Therapy for the Treatment of Venous Thromboembolism. Am J
Manag Care. 2003;9(5 suppl):S103-S114.
7. Turpie AG, Bauer KA, Eriksson BI, MD, Lassen MR, Fondaparinux vs Enoxaparin for the
Prevention of Venous Thromboembolism in Major Orthopedic Surgery. Arch Intern Med.
2002;162:1833-1840
8. Erickson AK. Fondaparinux approved for deep-vein thrombosis.Pharmacy Today 2002 from
www.medscape.com/viewarticle/436034
9. Pradaxa® Summary Product Characteristic, Boehringer Ingelheim Pharma
10. Xarelto® Summary of Product Characteristics, Bayer Schering Pharma AG
11. Eriksson Bl, J Bone Joint Surg BR. 2009; 91-B:636-644
1:53
1:31
2:34
1:11
2:36
0:50
1:06
1:44
1:05
1:07
0:44
0:36